Key statistics dashboard for Century Therapeutics, Inc. (IPSC). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments.
Stock Data
| Price | $1.86 |
| Market Cap | $161M |
| Enterprise Value | $146.0M |
| Beta | 1.67 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.90 |
| Price / Book | 1.75 |
| P/S | 0.00 |
| EV/EBITDA | -1.54 |
| EV/Sales | 0.00 |
| EV/FCF | -1.65 |
| P/FCF | -1.94 |
| Earnings Yield | -28.68% |
| FCF Yield | -54.98% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -52.76% |
| Return on Assets | -38.25% |
| Return on Invested Capital | -43.66% |
| Return on Capital Employed | -43.69% |
Financial Health
| Current Ratio | 8.28 |
| Quick Ratio | 8.28 |
| Cash Ratio | 3.29 |
| Debt / Equity | 0.15 |
| Debt / Assets | 12.06% |
| Net Debt / EBITDA | 0.16 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1.13 |
| Cash per share | 0.58 |
| FCF per share | -0.43 |
| Tangible Book Value per share | 0.96 |
| Dividend per share | 0.00 |
Related companies: COEP · CUE · EQ · GNTA · KPTI · MDCX · OSTX
Explore sector: Healthcare · Biotechnology
More sections of IPSC: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks